We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+40.64%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$587M
AUM Growth
+$37.7M
Cap. Flow
-$98.3M
Cap. Flow %
-16.76%
Top 10 Hldgs %
58.11%
Holding
52
New
10
Increased
8
Reduced
11
Closed
18

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$15.8M
2
NGNE icon
Neurogene
NGNE
+$14.2M
3
TRML
Tourmaline Bio
TRML
+$11.5M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$8.68M
5
VTGN icon
VistaGen Therapeutics
VTGN
+$7.03M

Top Sells

Rank Stock Value
1
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$19.4M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$11.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$11.2M
4
REPL icon
Replimune Group
REPL
+$10.9M
5
ACLX
Arcellx
ACLX
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-86,302
Closed -$3.76M
PNT
52
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-2,909,960
Closed -$19.4M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Great Point Partners held 52 positions worth $587M, up 6.9% from $549M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $98.3M in Q4 2023, closing 18 positions and reducing 11 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $19.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Abivax worth $16.6M.

  • Great Point Partners's largest Q4 2023 buy was Abivax: 1,550,000 shares worth $16.6M.
  • Great Point Partners added most to Tourmaline Bio in Q4 2023, an estimated $11.5M increase.
  • Great Point Partners's biggest Q4 2023 reduction was Arcellx, cutting an estimated $10.8M.
  • Great Point Partners fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $19.4M.
  • Great Point Partners's ten largest holdings make up 58% of its $587M portfolio in Q4 2023.
  • Great Point Partners opened 10 new positions and closed 18 in Q4 2023.
  • Great Point Partners's portfolio value rose 6.9% quarter-over-quarter to $587M.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.